文献速递腹部CTMR

LI-RADS 辐射治疗反应算法 v2024 对 Y-90 栓塞后的诊断表现

Diagnostic performance of CT/MRI LI-RADS radiation treatment response algorithm v2024 for Y-90 radioembolization.
PubMed 文献 · Eur J Radiol · 2026-07-14

本研究为单中心回顾性队列研究,纳入肝移植前最近一次局部治疗为 Y-90 放射性栓塞的患者。三名腹部放射科医生采用 LR-Radiation-TRA v2024 独立分类治疗后影像观察,并以移植肝病理为参考标准。结果显示该算法评估肿瘤活性具有高特异度,但阅片者间对活性判断的一致性和敏感度较低。

要点

  • LR-TR-Viable 对 Y-90 后肿瘤活性特异度高(92.9%),阳性结果较可信。
  • 阅片者间对 LR-TR-Viable 的判断一致性低(ICC=0.269),报告时需注意主观差异。
  • LR-TR-Nonviable 病灶病理仍有 31.2% 活性,不可仅凭影像完全排除活性。

核心结论

  • LI-RADS Radiation TRA v2024 对 Y-90 放射性栓塞后肝细胞癌肿瘤活性具有高特异度。
  • 尽管总体阅片一致性较高,但对 LR-TR-Viable 的阅片者间一致性低,提示相关定义和培训仍需改进。

研究设计与样本

  • 单中心回顾性队列研究,纳入肝移植前最近一次局部治疗为 Y-90 放射性栓塞的患者。
  • 98 例患者共 124 个观察病灶,由三名腹部放射科医生独立分类。
  • 参考标准为肝移植术后病理;一致性采用组内相关系数 ICC 计算。

诊断标准与关键数值

  • 372 次阅片中 LR-TR-Nonviable 占 66.4%(95% CI: 61.5 - 71.0%),LR-TR-Nonprogressing 占 25.5%(95% CI: 21.4 - 30.2%),LR-TR-Viable 占 7.5%(95% CI: 5.3 - 10.7%),LR-TR-Nonevaluable 占 0.5%(95% CI: 0.1 - 1.9%)。
  • 病理活性在 LR-TR-Nonviable、Nonprogressing、Viable 中分别为 31.2%、42.1%、53.6%(p=0.02)。
  • 排除 Nonprogressing 后,LR-TR-Viable 对肿瘤活性的敏感度为 16.3%(95% CI: 10.1 - 25.2%),特异度为 92.9%(95% CI: 88.2 - 95.8%)。
  • 逻辑回归显示 LR-TR-Viable 病灶较 Nonviable 病灶具有更高活性风险(OR=2.55, 95% CI 1.16 - 5.62, p=0.02)。
  • 平均成对阅片一致率为总体 89.8%(85.0 - 92.2%),CT 88.7%(82.3 - 92.0%),MRI 91.2%(83.3 - 94.2%);LR-TR-Viable 的 ICC=0.269(95% CI 0.098 - 0.425)。

临床应用与阅片要点

  • 日常报告中 LR-TR-Viable 阳性结果可用于提示肿瘤残留活性,因其特异度较高。
  • 阅片者之间对 Viable 判定存在明显差异,报告时建议结合多期增强特点并避免过度依赖单一分类。
  • LR-TR-Nonviable 病灶仍有较高病理活性比例,影像判读为无活性时不能完全除外残留活性。

局限性

  • 单中心回顾性设计,病例来源和阅片者经验可能影响外推性。
  • LR-TR-Viable 分类频次较低,导致阅片者间一致性估算不稳定且偏低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the performance and inter-reader agreement of the 2024 Liver Imaging Reporting and Data System (LI-RADS) Radiation Treatment Response Algorithm (LR-Radiation-TRA).

MATERIALS AND METHODS: This was a single-center retrospective cohort study of patients who underwent Y-90 radioembolization as their most recent locoregional therapy prior to liver transplantation. Three abdominal radiologists independently categorized each observation on the most recent post-treatment exams using LR-Radiation-TRA v2024. Diagnostic performance for tumor viability was determined using explant pathology as the reference standard, and inter-reader agreement was computed using intraclass correlation coefficients (ICCs).

RESULTS: 124 observations from 98 patients were categorized. Of the 372 total reads (3 per observation), 247 (66.4%, 95% CI: 61.5 - 71.0%) were LR-TR-Nonviable, 95 (25.5%, 95% CI: 21.4 - 30.2%) were -Nonprogressing, 28 (7.5%, 95% CI: 5.3 - 10.7%) were -Viable, and 2 (0.5%, 95% CI: 0.1 - 1.9%) were -Nonevaluable. The average pairwise agreement was 89.8% (85.0 - 92.2%) overall, 88.7% (82.3 - 92.0%) for CT, and 91.2% (83.3 - 94.2%) for MRI. Due to the low frequency of LR-TR-Viable categorization, inter-reader agreement for Viable versus Nonviable/Nonprogressing was low (ICC = 0.269, 95% CI 0.098 - 0.425). Viability on pathology was 31.2%, 42.1%, and 53.6% for Nonviable, Nonprogressing, and Viable respectively (p = 0.02). Excluding Nonprogressing, LR-TR-Viable achieved a sensitivity of 16.3% (95% CI: 10.1 - 25.2%) and specificity of 92.9% (95% CI: 88.2 - 95.8%) for viable tumor. Logistic regression showed higher odds of viability for LR-TR-Viable versus Nonviable lesions (OR = 2.55, 95% CI 1.16 - 5.62, p = 0.02).

CONCLUSION: LI-RADS-Radiation-TRA v2024 has high specificity for tumor viability after Y-90 radioembolization. While absolute agreement is high, inter-reader agreement for viability is low, suggesting the need for clearer definitions and training to potentially improve reliability in treatment response assessment for radiation-treated HCC.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Hong, Hassan, Tang, et al. Diagnostic performance of CT/MRI LI-RADS radiation treatment response algorithm v2024 for Y-90 radioembolization. Eur J Radiol. 2026. PMID: 42456618. doi:10.1016/j.ejrad.2026.113079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。